 "Lupin, Aurobindo surpasses Dr Reddy's in sales revenues")
The second largest Indian pharmaceutical company by sales till the last year, Dr Reddy's Laboratories Limited has slipped to fourth position among the top Indian generic generics players in 2016-17, after witnessing a 9 percent decline in revenues during the financial year.
The change in the pecking order was marked by the fall of its US generics revenues to below $1 billion level owing to fewer new launches as well as a steep price erosion of the existing products in the US market.
Mumbai-based Lupin Limited rose to the second place by registering a 24 per cent growth in consolidated
